Gary Brecka Longevity Claims: What Clinicians Should Tell Patients

Who Is Gary Brecka and Why Are Your Patients Asking?

Gary Brecka is the co-founder of 10X Health System, a concierge testing and supplement company, and a frequent guest on high-profile podcasts including The Ultimate Human with over one million YouTube subscribers. He describes himself as a "human biologist" who spent two decades in the life-insurance actuarial space predicting mortality. He holds no doctoral-level medical or research degree. His reach is large. A 2023 Pew Research analysis found that roughly 29% of U.S. Adults report getting health information from social-media influencers, which means a meaningful share of your patient panel has already heard his protocols presented as settled science.

What He Actually Claims

Brecka's publicly stated framework rests on four pillars: (1) genetic variant testing, chiefly MTHFR; (2) correcting "nutritional deficiencies" through methylated supplements; (3) testosterone and hormone optimization; and (4) lifestyle interventions including HBOT, cold exposure, and breathing exercises. In a widely circulated 2023 interview on the podcast Impact Theory, he stated, "The reason people are sick and dying early is that they're not getting the raw materials their genes require to express properly." That claim deserves clinical unpacking, not dismissal.

His Business Context

10X Health sells a blood and genetic panel marketed as a gateway to personalized supplementation. Clinicians should disclose this context to patients: the company that interprets the test also sells the supplements the test recommends. That does not make the underlying science wrong, but it is a conflict of interest patients deserve to know about.

The MTHFR Claim: What the Evidence Actually Shows

Brecka places MTHFR gene variants at the center of his longevity model, arguing that C677T and A1298C polymorphisms impair methylation, drive homocysteine elevation, and accelerate disease. The biology is real. The clinical leap is not fully supported.

Prevalence and Actual Risk

The MTHFR C677T TT homozygous genotype appears in roughly 10 to 15% of U.S. Adults and is associated with mildly elevated homocysteine. A 2012 meta-analysis in JAMA (N = 46,000 across 86 studies) found that homocysteine-lowering with B vitamins reduced stroke risk by approximately 11% in trials lasting 2 years or more, though cardiovascular mortality benefit was not consistently demonstrated. The American College of Medical Genetics 2013 guidelines explicitly state that MTHFR variant testing is not indicated for routine thrombophilia or cardiovascular risk evaluation in most clinical settings.

What Clinicians Should Order Instead

If a patient presents with elevated plasma homocysteine (above 15 micromol/L), the appropriate workup is homocysteine itself, B12, red-cell folate, and creatinine, not a direct-to-consumer gene panel. Treating a confirmed homocysteine elevation with methylfolate 400 to 1,000 mcg daily and methylcobalamin is reasonable and low-risk. Treating an MTHFR variant without measuring homocysteine is not supported by current ACMG guidance.

Methylated vs. Standard B Vitamins

One practical Brecka claim has genuine support. Individuals with C677T TT homozygosity may absorb methylfolate more effectively than folic acid. A 2014 randomized trial in the American Journal of Clinical Nutrition (N = 144) showed methylfolate raised red-cell folate more than equimolar folic acid in women with C677T variants. Recommending methylated B vitamins for documented homozygous MTHFR with elevated homocysteine is clinically reasonable. Recommending them to every patient based on a self-reported "biohacking" test is not.

Testosterone and Hormone Optimization

Brecka is a vocal advocate for testosterone replacement therapy in men he says are "functionally low," and he discusses hormone optimization in both sexes. The clinical picture here is more nuanced than his public statements suggest.

When TRT Is Appropriate

The Endocrine Society's 2018 Clinical Practice Guideline defines hypogonadism as a total testosterone below 300 ng/dL on two morning fasting measurements, confirmed with luteinizing hormone and follicle-stimulating hormone. In men with that confirmed diagnosis, FDA-approved testosterone formulations (testosterone cypionate injection, testosterone gel 1.62%, testosterone pellets) carry Level 1 evidence for improving libido, bone mineral density, lean body mass, and mood. The guideline explicitly recommends against prescribing to men with symptoms alone and normal lab values.

The TRAVERSE Trial Data

The 2023 TRAVERSE trial (N = 5,246, published in NEJM) demonstrated that testosterone therapy in middle-aged and older men with hypogonadism and elevated cardiovascular risk did not significantly increase major adverse cardiovascular events vs. Placebo over 33 months. That is reassuring news for appropriately selected patients. TRAVERSE also found a higher rate of atrial fibrillation (3.5% vs. 2.4%, P<0.001) and pulmonary embolism in the testosterone arm. Patients who hear Brecka call TRT universally safe need that caveat.

Female Hormone Optimization

Brecka discusses estrogen and progesterone replacement favorably and often references the 2002 Women's Health Initiative as "debunked." The accurate clinical framing: the WHI used conjugated equine estrogen plus medroxyprogesterone acetate in women aged 63 on average. The Menopause Society's 2023 Position Statement now endorses hormone therapy for menopausal symptom management in women under 60 or within 10 years of menopause onset without contraindications, a position consistent with what Brecka broadly advocates, though he rarely discusses the breast cancer risk data that still applies to combined estrogen-progestogen regimens beyond 5 years.

Hyperbaric Oxygen Therapy (HBOT)

Brecka describes HBOT as a powerful longevity tool, citing a 2020 Israeli study he says showed telomere lengthening. That study exists. Its conclusions require careful handling.

What the Shai-Efrati 2020 Study Actually Found

The Shai-Efrati group published a 2020 trial in Aging (Albany NY), N = 35 healthy adults over 64, showing that 60 sessions of 100% oxygen at 2 atmospheres absolute produced a 20% increase in peripheral blood mononuclear cell telomere length and a 37% reduction in senescent T-helper cells. That is a genuine peer-reviewed finding. The sample size is 35. There is no all-cause mortality endpoint. No replication trial has confirmed the finding in a larger cohort. Telomere length in PBMCs is a surrogate marker with disputed clinical meaning.

FDA-Cleared vs. Off-Label HBOT

The FDA has cleared HBOT for 14 specific indications including decompression sickness, diabetic foot ulcers, and carbon monoxide poisoning. Longevity and anti-aging are not among them. At-home HBOT chambers operating at 1.3 to 1.5 atmospheres are the most common consumer product; the Shai-Efrati study used 2 atmospheres in a hospital-grade chamber. Patients should know those are not equivalent.

Breathwork and Cold Exposure

Brecka frequently recommends Wim Hof-style breathing and cold-water immersion as daily practices. The science here is early but more encouraging than the HBOT longevity data.

Autonomic and Immune Effects

A 2014 PNAS study (N = 24) randomized trained Wim Hof practitioners vs. Controls to endotoxin challenge and found the trained group showed significantly lower plasma TNF-alpha, IL-6, and IL-8 responses, suggesting voluntary regulation of the innate immune response. The authors were careful to note the effect could not yet be separated from the cold exposure component. For most healthy patients, short-duration breathwork and brief cold-water immersion carry low risk and may improve autonomic resilience.

Safety Considerations

Cyclic hyperventilation preceding breath-holds (the full Wim Hof method) has been associated with syncope and drowning in several case reports. Clinicians should advise patients never to practice breath-holds in or near water. Patients with uncontrolled hypertension or cardiovascular disease should get clearance before cold immersion.

The Supplement Stack: What Brecka Takes and Recommends

Based on public interviews and 10X Health marketing materials reviewed through January 2025, Brecka publicly describes a personal stack that includes the following. This is reconstructed from his own statements, not from private medical records.

Core Methylation Support

• Methylfolate (L-5-MTHF), typically 400 to 1,000 mcg daily
• Methylcobalamin (B12), 1,000 to 5,000 mcg daily, often sublingual
• Riboflavin (B2), 100 mg daily (a cofactor for MTHFR enzyme activity)

Riboflavin supplementation for MTHFR support has a biological rationale. A 2016 RCT in the American Journal of Clinical Nutrition (N = 146) showed that 1.6 mg/day riboflavin lowered homocysteine by an additional 22% in C677T TT homozygotes already on folate therapy.

Glutathione and NAC

Brecka emphasizes intravenous and liposomal glutathione. Oral glutathione bioavailability is limited; a 2015 clinical trial (N = 54) in the European Journal of Nutrition showed that 500 mg/day oral glutathione raised whole-blood glutathione 30 to 35% over 6 months vs. Placebo. N-acetylcysteine (NAC), which serves as a glutathione precursor, has more consistent oral bioavailability. Neither compound has a controlled longevity endpoint in humans.

Testosterone (Self-Reported)

Brecka has discussed his own testosterone therapy in several podcast appearances, framing it as correction of a diagnosed deficiency. He has not published his lab values publicly, so no independent verification is possible.

Omega-3 Fatty Acids

Brecka recommends high-dose omega-3s (often 2 to 4 g EPA/DHA daily). The REDUCE-IT trial (N = 8,179) showed that icosapentaenoic acid 4 g daily (Vascepa) reduced major cardiovascular events by 25% vs. Placebo in statin-treated patients with elevated triglycerides. That trial applied to a specific high-risk population. Prescribing high-dose omega-3 to healthy patients for longevity extrapolates beyond the trial design.

Evaluating Brecka's Broader Longevity Framework

Brecka frequently cites the concept of "genetic expression" and argues that most chronic disease is rooted in nutrient-gene mismatch rather than inevitable aging. This is a version of nutrigenomics, a field with genuine academic standing at institutions like NIH's National Human Genome Research Institute, though it remains far from clinical translation for the majority of his claims.

Where His Framework Aligns With Evidence

• Correcting documented micronutrient deficiencies reduces morbidity. Full stop.
• TRT in confirmed hypogonadism has strong evidence for quality-of-life endpoints.
• Menopausal HRT in appropriate candidates is endorsed by the Menopause Society.
• Regular aerobic and resistance exercise remains the single intervention with the broadest longevity evidence base, and Brecka consistently endorses it.

Where the Evidence Gap Is Widest

• Routine MTHFR gene testing without homocysteine measurement is not guideline-supported.
• HBOT for longevity in healthy adults rests on a 35-person pilot study.
• Claims that his protocols can predict exact lifespan (he has quoted specific "time-to-death" figures in interviews) have no actuarial methodology in the public domain.

A Note on Motivated Reasoning

Patients who follow Brecka often report feeling better after adopting his protocols. That is real. Correcting B12 deficiency in someone who was subclinically depleted produces genuine improvement. Structured sleep, cold exposure, and breathwork all have positive psychophysiological effects. The risk is not that patients feel better. The risk is that they replace guideline-based care with unmonitored supplement stacks and delay evaluation of treatable conditions.

A Practical Clinician Checklist for Brecka-Influenced Patients

Patients who arrive already following Brecka's advice should be met with curiosity before correction. Most of them are motivated and health-engaged, which is an asset. The following lab panel covers the biologically plausible components of his framework.

Suggested Baseline Labs

• Complete metabolic panel including creatinine and liver function (monitors for supplement hepatotoxicity)
• CBC with differential (B12/folate deficiency screen)
• Plasma homocysteine (the clinically relevant MTHFR downstream marker)
• B12 and red-cell folate
• 25-hydroxyvitamin D
• Morning total and free testosterone (men), SHBG
• Estradiol, FSH, LH (women in perimenopause)
• Fasting lipids with triglycerides
• hs-CRP
• Thyroid-stimulating hormone

MTHFR genotyping can be ordered if homocysteine is elevated and the result would change management. Ordering it as a first-line screen without the downstream marker is not recommended by ACMG Practice Guidelines.

Counseling Points

Tell patients: "Some of what Brecka recommends matches what we would prescribe for the same lab finding. The difference is that we order the lab first, confirm the deficiency, and then treat it at a monitored dose."

That framing is accurate, non-dismissive, and keeps patients in your practice rather than pushing them to seek care entirely outside it.